Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease

RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related IRD.

Read more at globenewswire.com